Markets

Ascendis Pharma Reports Sustained Kidney Function Improvements Over 5-Years With TransCon PTH In Adults With Hypoparathyroidism

Oct 26, 2026 · 08:10 AM ET· updated 1h ago

Ascendis Pharma A/S (NASDAQ:ASND) today announced new data demonstrating early, sustained, and clinically meaningful improvements in kidney function in adults with hypoparathyroidism treated with TransCon® PTH

Why It Matters

Ascendis Pharma's medicine helped sick patients keep their kidneys working well for five years. This good safety news might make people more confident the company's treatment actually works.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ASND243.37

+0.38 (+0.16%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.